What is NewAmsterdam Pharma Company N.V's earnings per share (EPS)?

NewAmsterdam Pharma Company N.V (NAMS) reported diluted earnings per share of $-1.72 for fiscal year 2025. This represents a 32.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

NewAmsterdam Pharma Company N.V Financials

NAMS

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows NewAmsterdam Pharma Company N.V (NAMS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI NAMS FY2025 2026-05-07

Prior financing rather than current revenue still funds this business, with R&D-led operating burn dominating cash use.

From FY2023 to FY2025, operating cash burn stayed in a narrow band of $141M to $159M while revenue moved from $14.1M to $45.6M and back to $22.5M. That pattern says the business is still being run around a development budget, with R&D of $141.8M in FY2025 overwhelming the revenue base.

The balance sheet is cash-heavy: FY2025 ended with $490.0M of cash against just $85.9M of total liabilities and a 7.9x current ratio. That means near-term financing pressure looks more about the pace of cash burn than about debt service or working-capital tightness on the balance sheet today.

Cash use is also asset-light: free cash flow of -$148.0M was almost identical to operating cash flow of -$147.8M, while capital spending was only $246K. With shares outstanding rising from 82.5M in FY2023 to 115.0M in FY2025, the company has mainly financed this burn through equity capital rather than fixed-asset investment or borrowing.

Financial Health Signals

Financial Health Score 67/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of NewAmsterdam Pharma Company N.V's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Dilution

R&D Intensity

Revenue Progress

Burn Trend

Balance Sheet

Altman Z-Score Safe

27.94

NewAmsterdam Pharma Company N.V scores 27.94, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($4.2B) relative to total liabilities ($85.9M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

2/7

NewAmsterdam Pharma Company N.V passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality Low Quality

0.73x

For every $1 of reported earnings, NewAmsterdam Pharma Company N.V generates $0.73 in operating cash flow (-$147.8M OCF vs -$203.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$22.5M

YoY-50.6%

NewAmsterdam Pharma Company N.V generated $22.5M in revenue in fiscal year 2025. This represents a decrease of 50.6% from the prior year.

EBITDA

-$225.5M

YoY-28.0%

NewAmsterdam Pharma Company N.V's EBITDA was -$225.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 28.0% from the prior year.

Net Income

-$203.0M

YoY+16.1%

NewAmsterdam Pharma Company N.V reported -$203.0M in net income in fiscal year 2025. This represents an increase of 16.1% from the prior year.

EPS (Diluted)

$-1.72

YoY+32.8%

NewAmsterdam Pharma Company N.V earned $-1.72 per diluted share (EPS) in fiscal year 2025. This represents an increase of 32.8% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$148.0M

YoY+7.0%

NewAmsterdam Pharma Company N.V generated -$148.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 7.0% from the prior year.

Cash & Debt

$490.0M

YoY-36.5%

NewAmsterdam Pharma Company N.V held $490.0M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

115M

YoY+6.4%

NewAmsterdam Pharma Company N.V had 115M shares outstanding in fiscal year 2025. This represents an increase of 6.4% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

-1002.9%

YoY-616.0pp

NewAmsterdam Pharma Company N.V's operating margin was -1002.9% in fiscal year 2025, reflecting core business profitability. This is down 616.0 percentage points from the prior year.

Net Margin

-902.1%

YoY-371.0pp

NewAmsterdam Pharma Company N.V's net profit margin was -902.1% in fiscal year 2025, showing the share of revenue converted to profit. This is down 371.0 percentage points from the prior year.

Return on Equity

-29.7%

YoY+2.3pp

NewAmsterdam Pharma Company N.V's ROE was -29.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 2.3 percentage points from the prior year.

Capital Allocation

R&D Spending

$141.8M

YoY-6.3%

NewAmsterdam Pharma Company N.V invested $141.8M in research and development in fiscal year 2025. This represents a decrease of 6.3% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$246K

YoY-63.4%

NewAmsterdam Pharma Company N.V invested $246K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 63.4% from the prior year.

NAMS Income Statement

Metric	FY25	FY24	FY23	FY22	FY21
Revenue	$22.5M-50.6%	$45.6M+223.4%	$14.1M-86.3%	$102.7M	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$141.8M-6.3%	$151.4M-5.0%	$159.4M+83.8%	$86.7M+199.4%	$29.0M
SG&A Expenses	$106.4M+51.0%	$70.4M+87.2%	$37.6M+92.9%	$19.5M+225.0%	$6.0M
Operating Income	-$225.7M-28.0%	-$176.3M+3.6%	-$183.0M-5043.9%	-$3.6M+89.8%	-$35.0M
Interest Expense	N/A	N/A	N/A	$287K-30.2%	$411K
Income Tax	N/A	-$1K-103.7%	$27K	N/A	N/A
Net Income	-$203.0M+16.1%	-$242.0M-36.7%	-$177.0M-682.0%	-$22.6M+45.8%	-$41.8M
EPS (Diluted)	$-1.72+32.8%	$-2.56-19.1%	$-2.15-80.7%	$-1.19+68.8%	$-3.81

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$3.0M+9400.0%	$32K-90.8%	$348K-98.2%	$19.1M+542.9%	$3.0M-76.7%	$12.8M-56.1%	$29.1M+1177.4%	$2.3M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$38.0M-1.5%	$38.6M+24.6%	$31.0M+12.6%	$27.5M-38.5%	$44.8M+28.2%	$34.9M-2.3%	$35.7M-7.0%	$38.4M
SG&A Expenses	$23.5M-14.5%	$27.4M+11.8%	$24.5M-10.1%	$27.3M+0.4%	$27.2M+28.6%	$21.1M+14.6%	$18.4M+11.8%	$16.5M
Operating Income	-$58.4M+11.5%	-$66.0M-19.7%	-$55.1M-54.7%	-$35.6M+48.3%	-$68.9M-59.4%	-$43.2M-72.9%	-$25.0M+52.4%	-$52.6M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	-$1K	N/A
Net Income	-$48.4M+34.6%	-$74.1M-2.9%	-$72.0M-314.7%	-$17.4M+56.1%	-$39.5M+57.3%	-$92.6M-456.1%	-$16.6M+57.3%	-$39.0M
EPS (Diluted)	$-0.40	N/A	$-0.61-306.7%	$-0.15+55.9%	$-0.34	N/A	$-0.18+56.1%	$-0.41

NAMS Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21
Total Assets	$769.3M-11.0%	$864.6M+149.1%	$347.1M-27.5%	$478.5M	N/A
Current Assets	$675.7M-21.7%	$863.4M+149.0%	$346.8M-27.4%	$478.0M	N/A
Cash & Equivalents	$490.0M-36.5%	$771.7M+126.7%	$340.4M-27.2%	$467.7M	N/A
Inventory	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$85.9M-19.9%	$107.1M+82.5%	$58.7M+21.2%	$48.4M	N/A
Current Liabilities	$85.8M-19.8%	$106.9M+114.3%	$49.9M+38.4%	$36.1M	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A
Total Equity	$683.4M-9.8%	$757.5M+162.7%	$288.4M-32.9%	$430.1M+477.9%	-$113.8M
Retained Earnings	-$762.4M-36.5%	-$558.6M-76.2%	-$317.0M-126.4%	-$140.0M	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$732.6M-4.8%	$769.3M-2.2%	$786.4M-3.5%	$815.1M-0.4%	$818.4M-5.3%	$864.6M+96.9%	$439.2M-1.7%	$446.7M
Current Assets	$658.0M-2.6%	$675.7M-7.7%	$732.3M-4.9%	$769.9M-5.8%	$817.3M-5.3%	$863.4M+97.2%	$437.9M-1.7%	$445.4M
Cash & Equivalents	$457.6M-6.6%	$490.0M-9.0%	$538.4M-4.5%	$563.9M-24.7%	$748.4M-3.0%	$771.7M+82.6%	$422.7M-1.9%	$430.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$67.4M-21.5%	$85.9M+47.1%	$58.4M+59.4%	$36.6M-10.8%	$41.0M-61.7%	$107.1M+77.6%	$60.3M+1.8%	$59.3M
Current Liabilities	$67.4M-21.4%	$85.8M+47.2%	$58.3M+59.6%	$36.5M-10.8%	$40.9M-61.7%	$106.9M+159.2%	$41.3M-8.9%	$45.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$665.2M-2.7%	$683.4M-6.1%	$728.1M-6.5%	$778.5M+0.1%	$777.4M+2.6%	$757.5M+99.9%	$378.9M-2.2%	$387.4M
Retained Earnings	-$810.8M-6.4%	-$762.4M-10.9%	-$687.5M-11.7%	-$615.5M-2.9%	-$598.1M-7.1%	-$558.6M-19.8%	-$466.4M-3.7%	-$449.7M

NAMS Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21
Operating Cash Flow	-$147.8M+6.8%	-$158.6M-12.3%	-$141.2M-1424.1%	$10.7M+136.1%	-$29.5M
Capital Expenditures	$246K-63.4%	$672K+2700.0%	$24K-89.1%	$221K+820.8%	$24K
Free Cash Flow	-$148.0M+7.0%	-$159.2M-12.7%	-$141.2M-1452.4%	$10.4M+135.4%	-$29.5M
Investing Cash Flow	-$174.9M-178.3%	-$62.8M-261766.7%	-$24K+89.1%	-$221K-820.8%	-$24K
Financing Cash Flow	$29.5M-95.5%	$659.5M+7300.2%	$8.9M-97.7%	$391.9M+362.7%	$84.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$30.6M+25.1%	-$40.9M-24.7%	-$32.8M+13.0%	-$37.7M-3.3%	-$36.5M+2.7%	-$37.5M-199.8%	-$12.5M+76.8%	-$54.0M
Capital Expenditures	$38K-62.0%	$100K+138.1%	$42K-52.3%	$88K+450.0%	$16K+433.3%	$3K-96.0%	$75K-64.1%	$209K
Free Cash Flow	-$30.6M+25.2%	-$41.0M-24.9%	-$32.8M+13.1%	-$37.8M-3.5%	-$36.5M+2.7%	-$37.5M-198.0%	-$12.6M+76.8%	-$54.2M
Investing Cash Flow	-$11.5M+45.6%	-$21.1M-943.6%	$2.5M+101.6%	-$159.1M-5673.9%	$2.9M+104.6%	-$62.2M-82805.3%	-$75K+64.1%	-$209K
Financing Cash Flow	$11.1M-19.1%	$13.7M+132.2%	$5.9M+72.0%	$3.4M-47.5%	$6.5M-98.6%	$456.6M+787160.3%	$58K-98.8%	$4.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

NAMS Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Margin	-1002.9%-616.0pp	-386.9%+911.6pp	-1298.6%-1295.1pp	-3.5%	N/A
Net Margin	-902.1%-371.0pp	-531.1%+725.1pp	-1256.2%-1234.2pp	-22.0%	N/A
Return on Equity	-29.7%+2.3pp	-31.9%+29.4pp	-61.4%-56.1pp	-5.3%	N/A
Return on Assets	-26.4%+1.6pp	-28.0%+23.0pp	-51.0%-46.3pp	-4.7%	N/A
Current Ratio	7.88-0.2	8.08+1.1	6.95-6.3	13.26	N/A
Debt-to-Equity	0.13-0.0	0.14-0.1	0.20+0.1	0.11	N/A
FCF Margin	-657.8%-308.3pp	-349.5%+652.9pp	-1002.4%-1012.6pp	10.2%	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-1921.7%+204265.8pp	-206187.5%-190341.8pp	-15845.7%-15659.6pp	-186.1%+2128.3pp	-2314.5%-1976.0pp	-338.5%-252.6pp	-85.9%+2221.0pp	-2306.9%
Net Margin	-1593.5%+229981.6pp	-231575.0%-210883.9pp	-20691.1%-20600.4pp	-90.7%+1236.6pp	-1327.3%-602.4pp	-724.9%-667.7pp	-57.2%+1654.4pp	-1711.6%
Return on Equity	-7.3%+3.6pp	-10.8%-1.0pp	-9.9%-7.7pp	-2.2%+2.8pp	-5.1%+7.1pp	-12.2%-7.8pp	-4.4%+5.7pp	-10.1%
Return on Assets	-6.6%+3.0pp	-9.6%-0.5pp	-9.2%-7.0pp	-2.1%+2.7pp	-4.8%+5.9pp	-10.7%-6.9pp	-3.8%+4.9pp	-8.7%
Current Ratio	9.76+1.9	7.88-4.7	12.57-8.5	21.08+1.1	19.98+11.9	8.08-2.5	10.61+0.8	9.83
Debt-to-Equity	0.10-0.0	0.13+0.0	0.08+0.0	0.050.0	0.05-0.1	0.14-0.0	0.160.0	0.15
FCF Margin	-1008.0%+127038.9pp	-128046.9%-118618.4pp	-9428.4%-9231.2pp	-197.2%+1027.9pp	-1225.1%-931.6pp	-293.5%-250.3pp	-43.2%+2334.5pp	-2377.7%

Similar Companies

Ultragenyx Pharm RARE

$3.4B

Viking Therapeutics Inc VKTX

$4.8B

Mineralys Therapeutics, Inc. MLYS

$2.6B

Apellis Pharmace APLS

$5.3B

Crinetics Pharmaceuticals CRNX

$8.9B

Frequently Asked Questions

What is NewAmsterdam Pharma Company N.V's annual revenue?

NewAmsterdam Pharma Company N.V (NAMS) reported $22.5M in total revenue for fiscal year 2025. This represents a -50.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is NewAmsterdam Pharma Company N.V's revenue growing?

NewAmsterdam Pharma Company N.V (NAMS) revenue declined by 50.6% year-over-year, from $45.6M to $22.5M in fiscal year 2025.

Is NewAmsterdam Pharma Company N.V profitable?

No, NewAmsterdam Pharma Company N.V (NAMS) reported a net income of -$203.0M in fiscal year 2025, with a net profit margin of -902.1%.

What is NewAmsterdam Pharma Company N.V's EBITDA?

NewAmsterdam Pharma Company N.V (NAMS) had EBITDA of -$225.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is NewAmsterdam Pharma Company N.V's operating margin?

NewAmsterdam Pharma Company N.V (NAMS) had an operating margin of -1002.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is NewAmsterdam Pharma Company N.V's net profit margin?

NewAmsterdam Pharma Company N.V (NAMS) had a net profit margin of -902.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is NewAmsterdam Pharma Company N.V's return on equity (ROE)?

NewAmsterdam Pharma Company N.V (NAMS) has a return on equity of -29.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is NewAmsterdam Pharma Company N.V's free cash flow?

NewAmsterdam Pharma Company N.V (NAMS) generated -$148.0M in free cash flow during fiscal year 2025. This represents a 7.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is NewAmsterdam Pharma Company N.V's operating cash flow?

NewAmsterdam Pharma Company N.V (NAMS) generated -$147.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are NewAmsterdam Pharma Company N.V's total assets?

NewAmsterdam Pharma Company N.V (NAMS) had $769.3M in total assets as of fiscal year 2025, including both current and long-term assets.

What are NewAmsterdam Pharma Company N.V's capital expenditures?

NewAmsterdam Pharma Company N.V (NAMS) invested $246K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does NewAmsterdam Pharma Company N.V spend on research and development?

NewAmsterdam Pharma Company N.V (NAMS) invested $141.8M in research and development during fiscal year 2025.

How many shares does NewAmsterdam Pharma Company N.V have outstanding?

NewAmsterdam Pharma Company N.V (NAMS) had 115M shares outstanding as of fiscal year 2025.

What is NewAmsterdam Pharma Company N.V's current ratio?

NewAmsterdam Pharma Company N.V (NAMS) had a current ratio of 7.88 as of fiscal year 2025, which is generally considered healthy.

What is NewAmsterdam Pharma Company N.V's debt-to-equity ratio?

NewAmsterdam Pharma Company N.V (NAMS) had a debt-to-equity ratio of 0.13 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is NewAmsterdam Pharma Company N.V's return on assets (ROA)?

NewAmsterdam Pharma Company N.V (NAMS) had a return on assets of -26.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is NewAmsterdam Pharma Company N.V's cash runway?

Based on fiscal year 2025 data, NewAmsterdam Pharma Company N.V (NAMS) had $490.0M in cash against an annual operating cash burn of $147.8M. This gives an estimated cash runway of approximately 40 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is NewAmsterdam Pharma Company N.V's Altman Z-Score?

NewAmsterdam Pharma Company N.V (NAMS) has an Altman Z-Score of 27.94, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is NewAmsterdam Pharma Company N.V's Piotroski F-Score?

NewAmsterdam Pharma Company N.V (NAMS) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are NewAmsterdam Pharma Company N.V's earnings high quality?

NewAmsterdam Pharma Company N.V (NAMS) has an earnings quality ratio of 0.73x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is NewAmsterdam Pharma Company N.V?

NewAmsterdam Pharma Company N.V (NAMS) scores 67 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.